ACCP Mentors

First Name	***Last Name***	***Degree(s)***	***Affiliation***	***Country***	***Specialty Area***	***Group to Mentor***
Vikram	Arya	PhD	Government/Regulatory	US	Dr. Vikram Arya earned his Ph.D. in Pharmaceutics from the University of Florida. He has published articles on drug-drug interactions and impact of transporter modulation on drug disposition and has presented at various conferences. He is a Fellow of the American College of Clinical Pharmacology (ACCP) and currently serves as President-Elect of ACCP. He holds an Adjunct Clinical Professor appointment in the Department of Pharmacy Practice at Mercer University, Atlanta, GA, Adjunct Assistant Professor appointment in the Department of Pharmaceutical Sciences at the University of Tennessee, Adjunct Associate Professor appointment in the Department of Pharmaceutics, University of Florida, and Adjunct Professor appointment in the Department of Pharmacotherapy in the University of North Texas System College of Pharmacy. He serves on the Editorial Board of the Journal of Clinical Pharmacology (JCP) and International Journal of Clinical Pharmacology and Therapeutics (IJCPT).	Young Professionals Industry/Regulatory Track
Joe	Bertino	PharmD	Consulting	US	Dr Bertino has experience in both Pediatric and Adult Clinical Pharmacology, in patient care, research and teaching. He is currently the Editor-in-Chief of the Journal of Clinical Pharmacology. His expertise included drug metabolism and PK/PD application for drugs.	Students & Trainees, Academic junior faculty
Gouri	Bhattacharyya	MD, PhD	Clinical	India	Dr. Bhattacharyya is a Medical Oncologist & Clinical Hematologist, with special interests in drug development and drug repurposing. He is adept in clinical drug evaluation and impact, and is involved in research focused on drug mechanisms, pharmacogenomics, and toxicity.	
Lawrence	Cohen	PharmD	Academia	US	Dr. Cohen's research and scholarly interests include development of new/novel treatments for psychiatric disorders, pharmacokinetics and pharmacodynamics of psychotropic medications, geriatric psychopharmacology, pharmacoeconomics and health outcomes, pharmacoepidemiology, health disparities and emergency preparedness (specifically, access and affordability of healthcare during times of crisis).	
Matthew	Dufek	PhD	Industry	US	Dr. Dufek is Director of Clinical pharmacology at Abbvie in the department of clinical pharmacology and pharmacometrics (since 2013). IHe is the lead clinical pharmacology representative on the global development teams within the General Medicine Therapeutic Area. Some of the compounds he currently supports are in the therapeutic areas of cystic fibrosis, oncology, anti-infective (HIV and HCV), men's & women's health (endometriosis and fibroids), renal disease, pediatric and mature products. The majority of his responsibilities are leading the development of and strategic planning of clinical development plans for the execution of Phase 1-3 clinical studies within these project teams and review of proposals with executive management and governance committees. Other responsibilities have included, serving as clinical pharmacology team lead and steering committee member for external collaborations between AbbVie and other pharmaceutical development companies (US and Global) and external asset review and due diligences.	Students & Trainees (PhD and post-doc); Young Professionals Industry Track
Mike	Fossler	PharmD, PhD, FCP	Industry	US	Michael J. Fossler is Vice-President, Clinical Development and Quantitative Sciences, at Trevena, Inc. From 1995 to 2000, Dr. Fossler was employed by the FDA as a clinical pharmacology reviewer in the Division of Metabolic and Endocrine Drug Products. In 1998, he was promoted to Senior Reviewer, and joined the Pharmacometrics group at FDA, where he was responsible for reviewing and performing population PK/PD analyses. He left the Agency in 2000 and joined the Clinical Pharmacokinetics Group at DuPont Pharmaceuticals, where he had major responsibility for PK/PD analyses in the cardiovascular and anti-inflammatory areas. In November, 2001, he joined GlaxoSmithKline, where he continued to work in the cardiovascular area, and eventually headed a group of nine pharmacometrics scientists. He left GSK in 2015 to assume his present role at Trevena, Inc., where he heads up clinical pharmacology, clinical operations, biostatistics, programming and data management. He received a Pharm. D. (1992) and Ph. D. (1995) degrees from the University of Maryland. Dr. Fossler is a Fellow of the American Foundation for Pharmaceutical Education, a Fellow of the American College of Clinical Pharmacology, a past President of the College and is an Honorary Regent. He holds adjunct faculty appointments at the University of Maryland School of Pharmacy, Mercer University, and the University of North Texas, and is on the faculty of the University of California's American Course on Drug Development and Regulatory Science.	
John	Foxworth	PharmD	Academia	US	Dr. Foxworth's research interests are in evidence-based medicine. Dr. Foxworth works with students and residents teaching research methodology, biostatistics and evidence-based medicine.	

Tushar	Garimella	PhD	Industry	US	Dr. Garimella is an industry professional with more than 12 years of experience in Clinical Pharmacology and Pharmacometrics in multiple therapeutic areas. Currently employed in Bristol-Myers Squibb as therapeutic area head for Clinical Pharmacology for Cardiovascular assets, Tushar has experience across all phases of drug development. Previous experience includes hepatitis C, neuroscience and CKD and extensive experience in model informed drug development and regulatory interactions with multiple agencies including FDA, EMA, PMDA, KFDA, CDE and TFDA.	Students & Trainees (undergrad, graduate, post-doc); Young Professionals Industry/Regulatory Track
Navin	Goyal	PhD	Industry	US	Dr. Goyal has 8 years of experience in Clinical Pharmacology and Pharmacometrics working in Industry (GlaxoSmithKline) in different therapy areas. He is happy to share experience and mentor trainees/young professionals of what skills they need to sharpen, what should they expect when joining the industry at entry level positions.	Students & Trainees; Young Professionals Industry/Regulatory
Oliver	Grundmann	PhD	Academia	US	Dr. Grundmann received a bachelor's degree in pharmacy and European pharmacist license from the University of Münster, Germany, in 2004 before beginning his graduate studies at the University of Florida. While continuing his Ph.D. in Pharmaceutical Sciences, he worked for the Forensic Science program after graduating with a master's degree in Forensic Toxicology and minor in Statistics. His research interests include the search for new treatment options from natural products for Central Nervous System and Gastrointestinal diseases such as anxiety and depressive disorders as well as irritable bowel syndrome and cancers of the gastrointestinal tract. He also is interested in the implementation and impact of national and international collaborations for curricular development in the health sciences with an emphasis on distance and online education. Dr. Grundmann serves as the Director and faculty advisor for the online Master of Science and graduate certificate programs in Pharmaceutical Chemistry and Clinical Toxicology at the College of Pharmacy.	
Neeraj	Gupta	PhD	Industry	US	Dr. Gupta is an expert in clinical pharmacology and pharmacometrics and has extensive experience as a drug developer in oncology drug development. He holds a PhD degree in Pharmaceutics from the Univ of Iowa with specialization in pharmacokinetic/pharmacodynamic sciences. He has held positions in the pharmaceutical industry at Abbott and Millennium/Takeda. Currently at Takeda, Dr. Gupta leads a group of PhD-level clinical pharmacologists responsible for representing the discipline on drug development program teams from translational research through late-stage clinical development. He directly serves as the Global Clinical Pharmacology Leader for two of Takeda Oncology's marketed products, the proteasome inhibitor ixazomib for multiple myeloma and the ALK inhibitor brigatinib for ALK+ Non-small cell lung cancer, where his superior scientific and strategic leadership have been central to the development of these drugs. Dr. Gupta has published over 40 peer-reviewed papers in prestigious journals and over 90 abstracts/conference presentations at national and international meetings serving the communities of clinical pharmacology, translational medicine, cancer research, oncology clinical medicine and drug development/regulatory science. He has served as an invited speaker/faculty member or session chair at multiple major national and international meetings and at the FDA on topics ranging from model-informed drug development, proarrhythmic risk assessment in drug development and clinical pharmacology/pharmacometrics in oncology drug development.	Students & Trainees, young professions (industry/regulatory) track
Silvia	Illamola	PhD	Academia	US	Dr. Illamola's research is focused on clinical pharmacology and pharmacometrics in neonatology and obstetrics. Of special interest is the influence of growth and development of often used medication on the pharmacokinetics and pharmacodynamics in newborns, children and infants. Additionally, her research includes the clinical pharmacology of medications during pregnancy and lactation.	Students & Trainees
Priyanka	Ingle	PhD	Consulting	US	Dr. Ingle-Jadhav is a Physician-Researcher specializing in Pharmaceutical Medicine, Clinical Pharmacology. One of the major areas of her research focuses on Complementary and Integrative Health Medicine involving both lab and clinical methods. She brings in expertise of diverse therapeutic areas like infectious diseases, immunology-autoimmune diseases, pathology, dermatology, diabetes and domains like Outcome research focusing on HRQOL studies. She received her medical degree and PhD in Pharmaceutical Medicine from State Health University, Mumbai, India and postdoctoral training at UF diabetes institute, University of Florida, Gainesville, Florida. She has published several peer reviewed research articles in reputed research journals, co-edited a book, authored chapters in books, presented at national and international conferences, won many awards and also contribute as associate editor to the Journal of Ayurveda and Integrative Medicine.	
Manoj	Jadhav	PhD	Industry	US	Dr. Jadhav is a PhD in Pharmaceutical Technology and a trained clinical pharmacologist. He has worked on both non-clinical and clinical drug development programs in infectious diseases and cardiovascular diseases both in India and USA. He has published over 25 research papers in peer reviewed journals and has worked at both industry and academia.	Students & Trainees, young professionals (industry/regulatory) track

Michael	Jann	PharmD	Academia	US	Dr. Jann is a Professor and Chair in the Dept of Pharmacotherapy at the Univ of North Texas Health Sciences Center where his expertise is in drug development of CNS drugs. His specific research areas includes pharmacokinetics, pharmacodynamics, and clinical trial design.	Students & Trainees; academic research track
Jahnavi	Kharidia	PhD, RPh, RAC	Industry	US	Dr. Kharidia is the Director of Clinical Pharmacology at Sunovion Pharmaceuticals. She has a PhD in pharmacokinetics from the Univ of Maryland and has worked at the FDA, NIH and various pharma companies. She 21 years of experience in the field of clinical pharmacology. She has also previously volunteered mentor in Health Business Women Association	Young Professionals under Industry/Regulatory track
Ahmed	Nader	PhD	Industry	US	Dr. Nader is the Assoc Director of Clinical Pharmacology & Pharmacokinetics at AbbVie Inc.	Students & Trainees, young professionals (industry/regulatory) track
Anne	Paccaly	PharmD, PhD	Industry	US	Director in Quantitative Clinical Pharmacology at REGENERON since 2015, where she oversees the development and drug registration of biologics in immuno-oncology and inflammation. She has a PharmD and Hospital Pharmacist Degree from the Rijksuniversiteit of Gent (Belgium), a Degree in Pharmacokinetics & Metabolism (DESS) from the Université Paris XI, and a Doctorate Degree (PhD) in Clinical Pharmacology from the Université Paris V René Descartes (France), obtained while pursuing her career in the USA.	Students & Trainees
Arun	Ram	MD	Consulting	US	Dr. Ram has the unique combination of experience from clinical research and academia. Dr. Ram has successfully served in leadership positions in pharmacovigilance and medical writing areas for some of the top global pharmaceutical companies including Novartis and Pfizer. He is currently pursuing his passion in medical education and is now serving as an Associate Professor and Course Director in Eastern Virginia Medical School, VA, USA. He is an ECFMG certified physician who has won several recognitions and awards for his contribution to medical education and research.	Students & Trainees
Ahmed	Salem	PhD	Industry	US	Dr. Ahmed Salem is an associate director of Clinical Pharmacology and Pharmacometrics at AbbVie, North Chicago, USA, where he leads a group of clinical pharmacologists supporting the development of targeted anti-cancer agents. Dr. Salem is a pharmacist and holds a PhD in Clinical Pharmacology from University of Minnesota with minor in Biostatistics. Dr. Salem's research at University of Minnesota focused on pharmacometric analyses of anti-HIV and anti-MRSA agents. In the industry, Dr. Salem has supported the clinical development of small and large molecules in the oncology, virology and women's health therapeutic areas. Dr. Salem has contributed to the approval of several new and supplemental drug applications and marketing authorization applications. His most recent accomplishment was leading the clinical pharmacology strategy for the first-in-class BCL-2 inhibitor; venetoclax, contributing to its approval in the US and EU. Dr. Salem has published over 80 peer-reviewed publications including 33 original research articles. Dr. Salem serves on the STYP Committee of the American College of Clinical Pharmacology (ACCP) and on the publications committee of the International Society of Pharmacometrics (ISoP). He is also a peer review for numerous clinical pharmacology journals and is a member of the Rho Chi pharmacy Phi Kappa Phi Honor societies.	Young Professionals/Industry Track
Mohamadi	Sarkar	M.Pharm., PhD, FCCP	Industry	US	Dr. Sarkar is a Fellow of Scientific Strategy at Altria Client Services LLC, and is an Affiliate Professor of Clinical Pharmacology at the Medical College of Virginia at VCU. He provides strategic direction towards developing the science and evidence for regulatory submissions for non-combustible tobacco products for Altria's tobacco operating companies. He has authored more than 100 scientific peer-reviewed publications and presentations at scientific meetings. Dr. Sarkar has also participated in multiple seminar presentations and authored a variety of scientific book chapters related to his areas of expertise.	
Nithya	Srinivas	PhD	Industry	US	Dr. Srinivas is a Senior Research Investigator at Incyte Pharmaceuticals specializing in clinical pharmacokinetics.	
Cynthia	Sung	PhD	Academia	Singapore	Dr. Sung is s an adjunct Associate Professor at the Signature Programme in Health Services and Systems Research, Duke-NUS. She has experience working for 2 regulatory agencies doing pre-market evaluation (FDA - IND and NDA evaluation for the Office of Clinical Pharmacology), and post-market safety surveillance and pharmacogenomics (Health Sciences Authority - Singapore). She also has 5 years of industry experience as Director of Pharmacokinetics (preclinical and clinical) at a mid-sized biotechnology company (Human Genome Sciences, Inc)	young professionals in the industry / regulatory track
John	van den Anker	MD, PhD	Academia	US	Johannes van den Anker, M.D., Ph.D., division chief of Clinical Pharmacology and vice chair of Pediatrics for Experimental Therapeutics at Children's National Health System. Dr. van den Anker specializes in pediatric pharmacology and therapeutics, and his workexpanded and enhanced medical knowledge about the use of drugs in children and about the treatment of disease. He has also played an integral role in training the next generation of clinical pharmacists and pharmacologists.	

Peter	Wiernik	MD	Non-profit	US	Dr. Wiernik is the founder of the Comprehensive Cancer Center at Our Lady of Mercy Medical Center in New York and served as Director until 2009. He is currently a member of the Board of Regents of the ACCP, and is also the immediate past Chair of the Eastern Division of the American Federation of Medical Research. At various times in his career, he was Professor of Medicine and Radiation Medicine at the University of Maryland School of Medicine, Albert Einstein College of Medicine, and New York Medical College. He was Editor of Medical Oncology from 1993 to 2014, as well as Consulting Editor for the Journal of Clinical Oncology from 2009 to 2015. Dr. Wiernik was President of the American Radium Society from 1993 to 1994 and received the society's Janeway Gold Medal in 1996. Dr. Wiernik is the author of more than 700 peer-reviewed papers and a dozen books, including Neoplastic Diseases of the Blood, which is currently in its 5th edition.	